文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 3750-大鼠尿路感染In Vitro and In Vivo Antibacterial Activities of DK-507k, a
侵权投诉

3750-大鼠尿路感染In Vitro and In Vivo Antibacterial Activities of DK-507k, a

ANTIMICROBIALAGENTSANDCHEMOTHERAPY,Dec.2003,p.3750–37590066-4804/03/$08.00 0DOI:10.1128/AAC.47.12.3750–3759.2003

Copyright©2003,AmericanSocietyforMicrobiology.AllRightsReserved.

Vol.47,No.12

InVitroandInVivoAntibacterialActivitiesofDK-507k,a

NovelFluoroquinolone

TsuyoshiOtani,*MayumiTanaka,EmiIto,YuichiKurosaka,YoichiMurakami,

KiyomiOnodera,TakaakiAkasaka,andKenichiSato

NewProductResearchLaboratoriesI,DaiichiPharmaceuticalCo.Ltd.,Tokyo,Japan

Received21March2003/Returnedformodi cation8July2003/Accepted31August2003

TheantibacterialactivitiesofDK-507k,anovelquinolone,werecomparedwiththoseofotherquinolones:cipro oxacin,gati oxacin,levo oxacin,moxi oxacin,sita oxacin,andgarenoxacin(BMS284756).DK-507kwasasactiveassita oxacinandwasasactiveasoruptoeightfoldmoreactivethangati oxacin,moxi oxacin,andgarenoxacinagainstStreptococcuspneumoniae,methicillin-susceptibleandmethicillin-resistantStaphylo-coccusaureus,andcoagulase-negativestaphylococci.DK-507kwasasactiveasor4-foldmoreactivethangarenoxacinand2-to16-foldmoreactivethangati oxacinandmoxi oxacinagainstcipro oxacin-resistantstrainsofS.pneumoniae,includingclinicalisolatesandinvitro-selectedmutantswithknownmutations.DK-507kinhibitedallcipro oxacin-resistantstrainsofS.pneumoniaeat1 g/ml.Atime-killassaywithS.pneumoniaeshowedthatDK-507kwasmorebactericidalthangati oxacinandmoxi oxacin.TheactivitiesofDK-507kagainstmostmembersofthefamilyEnterobacteriaceaewerecomparabletothoseofcipro oxacinandequaltoorupto32-foldhigherthanthoseofgati oxacin,levo oxacin,moxi oxacin,andgarenoxacin.DK-507kwasfourfoldlessactivethansita oxacinandcipro oxacinagainstPseudomonasaeruginosa,whileitwastwotofourtimesmorepotentthanlevo oxacin,gati oxacin,moxi oxacin,andgarenoxacinagainstP.aeruginosa.Invivo,intravenoustreatmentwithDK-507kwasmoreeffectivethanthatwithgati oxacinandmoxi oxacinagainstsystemicinfectionscausedbyS.aureus,S.pneumoniae,andP.aeruginosainmice.Inamousemodelofpneumoniaduetopenicillin-resistantS.pneumoniae,DK-507kadministeredsubcutaneouslyshoweddose-dependentef cacyandeliminatedthebacteriafromthelungs,whereasgati oxacinandmoxi- oxacinhadnosigni cantef cacy.OraltreatmentwithDK-507kwasslightlymoreeffectivethanthatwithcipro oxacininaratmodelofforeignbody-associatedurinarytractinfectioncausedbyaP.aeruginosaisolateforwhichtheMICofDK-507kwasfourfoldhigherthanthatofcipro oxacin.OraladministrationofDK-507ktoratsachievedhigherpeakconcentrationsinserumandhigherconcentrationsincumulativeurinethanthoseachievedwithcipro oxacin.ThesedataindicatethepotentialadvantagesofDK-507koverotherquinolonesforthetreatmentofawiderangeofcommunity-acquiredinfections.

Ascommunity-acquiredpathogensareexhibitingincreasinglevelsofresistanceto -lactamsandmacrolides,quinoloneshaveemergedasoneofthe rst-linedrugsfortherapyforrespiratoryinfectionsandurinarytractinfectionsinthecom-munity(3,4,24).

Theapplicationofnewerquinolones,suchaslevo oxacin,gati oxacin,andmoxi oxacin,withenhancedpotenciesagainstgram-positivebacteriaforthetreatmentofcommunity-acquiredrespiratoryinfectionshasbecomeimportantbecauseoftheworldwideprevalenceofpenicillin-andmultidrug-resis-tantStreptococcuspneumoniaestrains(1,10,14,21,22).How-ever,eventhesenewerquinoloneshaverelativelyhighMICsthatmaylimittheirtherapeuticvalueagainstsomestrainsofcipro oxacin-resistantpneumococciforwhichtheMICsareclosetoorabovethebreakpoint(6,11,19,26).Ontheotherhand,community-acquiredurinarytractinfectionsareamongthemostcommonlyobservedinfectionsinclinicalpractice.Quinoloneshaveprimarilybeenusedfortherapyforpatientswithurinarytractinfections,inwhichgram-negativebacteriaarethemostcommoncausativeagents(8,16).Recenttrends,

however,oftheapplicationofquinolonesforthetreatmentofrespiratorytractinfectionsbyimprovingtheirantibacterialac-tivitiesagainstgram-positivebacteriaarelikelyassociatedwitharelativedecreaseinactivityagainstgram-negativebacteria,eveniftheactivitystillhastherapeuticvalue.Therefore,thedevelopmentofquinoloneswithpotentialutilityforthetreat-mentofinfectionscausedbybothgram-positiveandgram-negativebacteriawouldrepresentsigni cantprogress.

DK-507kisanovel uoroquinolonewiththechemicalstruc-tureshowninFig.1(K.Kawakamietal.,Abstr.41stIntersci.Conf.Antimicrob.AgentsChemother.,abstr.F-546,2001).DK-507kpossessedimprovedactivityagainstgram-positivebacteria,includingsomestrainsresistanttotheavailablequin-olones,whiletheactivityofthecompoundagainstgram-neg-ativebacteriawasmaintained.ToinvestigatethepotencyofDK-507kagainstabroadspectrumofbacterialpathogens,westudieditsinvitroantibacterialactivitiesagainstavarietyofrecentclinicalisolatesanditsinvivoef cacyinmousemodelsofsepticemiacausedbyS.pneumoniae,Staphylococcusaureus,Escherichiacoli,andPseudomonasaeruginosa;amousemodelofpneumococcalpneumonia;andaratmodelofforeignbody-associatedurinarytractinfectioncausedbyP.aeruginosa.Thecomparatoragentswerecipro oxacin,gati oxacin,levo oxa-cin,moxi oxacin,sita oxacin,andgarenoxacin(BMS284756).(Thisworkwaspresentedinpartatthe41stInterscience

3750

*Correspondingauthor.Mailingaddress:NewProductResearchLaboratoriesI,DaiichiPharmaceuticalCo.Ltd.,16-13Kitakasai1-Chome,Edogawa-ku,Tokyo134-8630,Japan.Phone:81-3-5696-8378.Fax:81-3-5696-4264.E-mail:otanir16@daiichipharm.co.jp.

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email